A detailed history of Cary Street Partners Financial LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Cary Street Partners Financial LLC holds 20,690 shares of HALO stock, worth $1.45 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
20,690
Previous 104,981 80.29%
Holding current value
$1.45 Million
Previous $5.46 Billion 72.21%
% of portfolio
0.04%
Previous 0.15%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 10, 2025

SELL
$52.92 - $78.28 $4.46 Million - $6.6 Million
-84,291 Reduced 80.29%
20,690 $1.52 Billion
Q2 2025

Aug 13, 2025

SELL
$47.91 - $70.14 $20,026 - $29,318
-418 Reduced 0.4%
104,981 $5.46 Billion
Q1 2025

May 09, 2025

BUY
$47.74 - $65.16 $298,136 - $406,924
6,245 Added 6.3%
105,399 $6.73 Billion
Q4 2024

Feb 14, 2025

BUY
$42.57 - $61.09 $4.22 Million - $6.06 Million
99,154 New
99,154 $4.74 Billion

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $9.75B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Cary Street Partners Financial LLC Portfolio

Follow Cary Street Partners Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cary Street Partners Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cary Street Partners Financial LLC with notifications on news.